Skip to main content

Market Overview

Equillium's Stock Is Trading Higher On Itolizumab's Durable, Sustained Response In Graft-Versus-Host Disease Study


Equillium Inc (NASDAQ: EQreports positive data from Phase 1b/2 Equate Study evaluating 'itolizumab' in acute graft-versus-host disease (aGVHD).

  • The data was presented at the virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation.
  • The study showed that a majority of patients achieved a complete response within 15 days, which was maintained through day 85.
  • A clinically meaningful reduction in corticosteroid use was observed in these patients, and 'itolizumab' inhibited pathogenic T cell proliferation.
  • Median steroid dose reduction at Day 85 was 93%, 87%, and 91% for Cohorts 1, 2, and 3, respectively.
  • Pharmacodynamic data from the first three cohorts suggests an optimal dose range of 0.8 to 1.6 mg/kg.
  • Itolizumab was generally well tolerated across all doses.
  • Strong response for higher dose level cohorts (0.8 and 1.6 mg/kg) was observed with an overall response rate of 100% (N=6) at day 29. Most have been complete responses.
  • Itolizumab is an anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway that plays a central role in modulating T cells that drive many immuno-inflammatory diseases.
  • Price Action: EQ shares are up 9.22% at $8.64 in market trading hours on the last check Monday.

Related Articles (EQ)

View Comments and Join the Discussion!

Posted-In: Phase 2 TrialBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at